| Schedule of financial information regularly reviewed and used by the CODM |
This decision making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
2024 |
|
|
2023 |
|
Revenues and other income |
|
|
|
|
|
Grant income |
$ |
— |
|
|
$ |
260,501 |
|
Costs and expenses: |
|
|
|
|
|
Research and development (excluding share-based compensation) expense: |
|
|
|
|
|
PAH |
|
1,672,869 |
|
|
|
— |
|
PD |
|
9,333,359 |
|
|
|
9,036,750 |
|
Other programs |
|
1,512,151 |
|
|
|
4,421,520 |
|
Selling, general and administrative (excluding share-based compensation) |
|
7,930,072 |
|
|
|
6,391,875 |
|
Share-based compensation expense |
|
8,140,617 |
|
|
|
500,148 |
|
Total costs and expenses |
|
28,589,068 |
|
|
|
20,350,293 |
|
Loss from operations |
|
(28,589,068 |
) |
|
|
(20,089,792 |
) |
Interest income |
|
1,069,182 |
|
|
|
1,060,909 |
|
Net loss |
$ |
(27,519,886 |
) |
|
$ |
(19,028,883 |
) |
|